['epithelial ovarian cancer', 'primary peritoneal carcinoma', 'fallopian tube cancer', 'ovarian cancer']
['mirvetuximab soravtansine', 'paclitaxel', 'pegylated liposomal doxorubicin', 'topotecan']

        Inclusion Criteria:

          -  Participants must be diagnosed with advanced epithelial ovarian cancer, primary
             peritoneal cancer or fallopian tube cancer

          -  Participants must have folate receptor alpha positive tumor expression as defined in
             the protocol

          -  Participants must have platinum-resistant ovarian cancer, defined as progression
             within 6 months from completion of a minimum of four cycles of platinum-containing
             therapy.

          -  Participants must have received at least one but no more than three prior systemic
             treatment regimens and for whom single-agent chemotherapy is appropriate as the next
             line of treatment

          -  Participants must have at least one lesion that meets the definition of measurable
             disease by RECIST 1.1

        Exclusion Criteria:

          -  Diagnosis of clear cell, low grade ovarian cancer or mixed tumors

          -  Participants with primary platinum-refractory disease

          -  Serious concurrent illness or clinically relevant active infection as defined in the
             protocol

          -  Prior treatment with mirvetuximab soravtansine

          -  Women who are pregnant or breast feeding
      